Benjamin Dorfman is a Neurology physician. OpenAlex indexes 12 publications with 1,293 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
280 South Main Street
Suite 102
Cheshire, CT 06410
Telephone
860-870-6385Provider last certified this registry record 19 Jul 2022.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Teva Pharmaceuticals USA, Inc.Program year20258 payments
- MDD US Operations, LLCProgram year20256 payments
- ABBVIE INC.Program year202511 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
91.2%Aromatic Amino Acid Decarboxylation Inhibitor38.7%Carbidopa-Levodopa69%Carbidopa-Levodopa Er19%Rytary10%Carbidopa-Levodopa-Entacapone1%Carbidopa1%Part D<11 patientsGabapentinoids7.8%Gabapentin80%Horizant20%Part D<11 patients+ 18 more classes in this area
Cardiovascular
8.8%Beta blocker7.8%Propranolol Hcl85%Propranolol Hcl Er15%Part D<11 patientsalpha-Adrenergic Agonist1%Midodrine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia
Expert Review of Neurotherapeutics
2020 - Neuroimaging Markers of Motor and Nonmotor Features of Parkinson's Disease: An [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Computed Tomography Study
Dementia and Geriatric Cognitive Disorders
2013
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”